cystic-fibrosis

Documents about cystic-fibrosis

• Phase I Pilot Study of Ad5-CB-CFTR, an Adenovirus Vector Containing the Cystic Fibrosis Transmembrane Conductance Regulator Gene, in Patients With Cystic Fibrosis#904566ClinicalTrials.gov
• Personalized Theratyping Trial#1030275ClinicalTrials.gov
• A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation#230452ClinicalTrials.gov
• Multiple defects in macrophage antibacterial responses support intracellular survival of Mycobacterium abscessus in cystic fibrosis#333907HAL (France)
• 19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease#831932ClinicalTrials.gov
• Safety and Tolerability Study of Allogeneic Mesenchymal Stem Cell Infusion in Adults With Cystic Fibrosis#840026ClinicalTrials.gov
• A Comparison of Clinical Parameters in With and Without Abnormal Glucose Tolerance.#845145ClinicalTrials.gov
• A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis#871477ClinicalTrials.gov
• FLAME: Airway Inflammation Monitoring in Asthma and Cystic Fibrosis#890692ClinicalTrials.gov
• Evaluation of the High Frequency Digit Triplet Test in Cystic Fibrosis#896161ClinicalTrials.gov
• Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation#902396ClinicalTrials.gov
• Bronchial Inflammation of Small Airways in Patients With Cystic Fibrosis#907152ClinicalTrials.gov
• Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis#908791ClinicalTrials.gov
• Use of Formula Fortified With DHA in Infants With Cystic Fibrosis#912396ClinicalTrials.gov
• Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation#992582ClinicalTrials.gov
• Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor#868665ClinicalTrials.gov
• Feasibility and Tolerance of High-Intensity Interval Training in Adults With Cystic Fibrosis#424880HAL (France)
• Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaid® in Patients With Cystic Fibrosis#141033ClinicalTrials.gov
• Evolution of body image across treatment eras: a systematic review in young people and adults living with cystic fibrosis#201241ULRR
• Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa#261317ClinicalTrials.gov
• Evaluation of the Emission Distance of P. Aeruginosa From the Respiratory Tract of People With Cystic Fibrosis#812432ClinicalTrials.gov
• Nasal Mucin Oral Supplementation Treatment Respiratory Inflammation Using PUFA in Cystic Fibrosis (CF) Patients#857560ClinicalTrials.gov
• Prospective Study of the Phenotypic Expression of Cystic Fibrosis (CF) Screened Positive Newborns With an Atypical Form of CF (DPAM)#858162ClinicalTrials.gov
• Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI)#858745ClinicalTrials.gov
• Platelets in Cystic Fibrosis Lung Inflammation#863369ClinicalTrials.gov
• Multiple Breath Nitrogen Washout in Healthy and Cystic Fibrosis Adults#863450ClinicalTrials.gov
• Video Game Exercise Effectiveness of a Domiciliary Pulmonary Rehabilitation Program in Cystic Fibrosis Patients#883311ClinicalTrials.gov
• Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa#885980ClinicalTrials.gov
• A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis#895694ClinicalTrials.gov
• Epidemiology of the Nasal Flora at the Reference Center for Cystic Fibrosis of Queen Fabiola Children's University Hospital.#906195ClinicalTrials.gov
• Vitamin D and Prebiotics for Intestinal Health in Cystic Fibrosis#913276ClinicalTrials.gov
• Ovarian Reserve in Women With Cystic Fibrosis and the Correlation With Demographic and Clinical Parameters#917619ClinicalTrials.gov
• Safety Study of Ivacaftor in Subjects With Cystic Fibrosis#912617ClinicalTrials.gov
• Performance and Patient Acceptance of a Commercially Available Beverage as Compared to an Oral Glucose Solution for Oral Glucose Tolerance Tests in Cystic Fibrosis (CF) Patients Who Are Screened for CF-related Diabetes.#870993ClinicalTrials.gov
• Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB)#887576ClinicalTrials.gov
• Home Airway Clearance in CF Patients#217077ClinicalTrials.gov
• The Microvascular Complications Study#298278ClinicalTrials.gov
• Controlled Ventilation CT in CF Infants#966596ClinicalTrials.gov
• Leucine-enriched Essential Amino Acid Intake to Optimize Protein Anabolism in Children With Cystic Fibrosis#832834ClinicalTrials.gov
• Early Intervention in Pulmonary Exacerbation in Cystic Fibrosis#834754ClinicalTrials.gov
• Resistive Inspiratory Manoeuvre as Airway Clearance Technique in Cystic Fibrosis#837778ClinicalTrials.gov
• Tobramycin Delivered by Nebulized Sonic Aerosol for Chronic Rhinosinusitis Treatment of Cystic Fibrosis Patients#849035ClinicalTrials.gov
• Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLIT™] Amikacin) in Participants With Cystic Fibrosis (CF) Having Chronic Infections of Pseudomonas Aeruginosa#853090ClinicalTrials.gov
• A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis#899665ClinicalTrials.gov
• Gut Imaging for Function and Transit in Cystic Fibrosis 3 Junior#910728ClinicalTrials.gov
• Safety and Efficacy of Recombinant Adeno-Associated Virus Containing the CFTR Gene in the Treatment of Cystic Fibrosis#912547ClinicalTrials.gov
• PEP and O-PEP Device for Nebulization in Cystic Fibrosis#915448ClinicalTrials.gov
• A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation#982039ClinicalTrials.gov
• Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del#992652ClinicalTrials.gov
• Molecular Diagnosis of Respiratory Viral Infections on Sputum From Cystic Fibrosis Patients#1032010ClinicalTrials.gov